Welltower stock maintains Buy rating at UBS on strong growth
UBS maintained a Buy rating and $269 price target for Welltower (WELL) after its Q3 2026 results. WELL reported 25% FFO growth, 38% revenue growth, and a 34% share return over the past year. The company acquired $4.1B in properties and raised its full-year FFO outlook. Despite an EPS miss, revenue exceeded expectations, and occupancy increased.
How this was made
The 30-second read
Why it matters
The upgrade and guidance raise are likely to attract buying interest, especially from income‑focused investors.
Market read
Earnings beat on revenue and a raised FFO outlook, combined with an analyst upgrade, create a strong near‑term bullish catalyst for WELL.
What to watch
Acquisition yield compression may cap future returns if occupancy growth slows.
Background
UBS analysts reaffirmed a Buy rating on WELL, citing strong FFO growth, robust acquisition activity, and an upgraded full‑year outlook.
Ticker impact
UBS reiterated a Buy rating and raised the price target to $269 after Welltower's Q3 2026 earnings miss on EPS but beat revenue and raised FFO guidance.
likely upward pressure as the market prices in the raised guidance and buy rating
The combination of a higher price target, a Buy rating, and an increased FFO outlook provides a clear catalyst for buying pressure.
Market effects
Strong senior‑housing REIT performance may lift other health‑care real‑estate stocks.
Positive news for U.S. REITs could support broader equity indices.
Limited to U.S. markets; no direct global macro effect.
Counterpoint
The EPS miss could signal underlying cost pressures that may limit upside.
Key entities
- companyWelltower, Inc.
U.S. health‑care REIT providing senior housing and post‑acute care.
- analyst_firmUBS
Investment bank that issued the Buy rating and price target.
